Monitoring Tumor Markers in Breast Cancer Treatment
Author Information
Author(s): Bartsch Rupert, Wenzel Catharina, Pluschnig Ursula, Hussian Dagmar, Sevelda Ursula, Altorjai Gabriela, Locker Gottfried J, Mader Robert, Zielinski Christoph C, Steger Guenther G
Primary Institution: Medical University of Vienna
Hypothesis
What is the prognostic value of monitoring tumor markers CA 15-3 and CEA during fulvestrant treatment in metastatic breast cancer patients?
Conclusion
CA 15-3 levels can increase in patients on fulvestrant treatment, but this should not be interpreted as disease progression without further verification.
Supporting Evidence
- In patients with partial response, CEA levels significantly decreased after 6 months.
- CA 15-3 levels increased significantly in patients with stable disease after 6 months.
- CA 15-3 and CEA levels increased significantly in patients experiencing de novo progression.
Takeaway
Doctors check certain markers in the blood to see how well cancer treatment is working, but sometimes these markers can go up even when the treatment is helping.
Methodology
Tumor markers CA 15-3 and CEA were monitored monthly in patients receiving fulvestrant treatment, and data were analyzed for changes in marker levels.
Potential Biases
Potential bias due to the compassionate use program and the retrospective analysis of some data.
Limitations
The study had a small sample size and the results may not be generalizable.
Participant Demographics
All participants were postmenopausal women with ER-positive and/or PgR-positive metastatic breast cancer.
Statistical Information
P-Value
P < 0.0001 for CA 15-3 in patients with stable disease and de novo progression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website